SAFETY DATA SHEET

Ezetimibe / Simvastatin Formulation

SECTION 1. IDENTIFICATION

Product name : Ezetimibe / Simvastatin Formulation

Manufacturer or supplier’s details
Company name of supplier : Merck & Co., Inc
Address : 2000 Galloping Hill Road
         Kenilworth - New Jersey - U.S.A. 07033
Telephone : 908-740-4000
Telefax : 908-735-1496
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use
Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with 29 CFR 1910.1200
Combustible dust
Skin irritation : Category 2
Skin sensitization : Category 1
Specific target organ toxicity - repeated exposure : Category 1 (Liver, muscle, optic nerve, Eye)

GHS label elements
Hazard pictograms : ![Signal Word:](image)

Precautionary Statements
Prevention: P260 Do not breathe dust. P264 Wash skin thoroughly after handling. P270 Do not eat, drink or smoke when using this product. P272 Contaminated work clothing must not be allowed out of the workplace. P280 Wear protective gloves.
Response:
SAFETY DATA SHEET

Ezetimibe / Simvastatin Formulation

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>Components</th>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>&gt;= 10 - &lt; 20</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ezetimibe</td>
<td>163222-33-1</td>
<td>&gt;= 10 - &lt; 20</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Simvastatin</td>
<td>79902-63-9</td>
<td>&gt;= 10 - &lt; 20</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>&gt;= 1 - &lt; 5</td>
</tr>
</tbody>
</table>

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention if symptoms occur.

In case of skin contact: In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: Causes skin irritation. May cause an allergic skin reaction. Causes damage to organs through prolonged or repeated exposure. Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during firefighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
Nitrogen oxides (NOx)
Fluorine compounds
Metal oxides

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters: In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures: Use personal protective equipment.
Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions: Discharge into the environment must be avoided.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spills cannot be contained.

Methods and materials for containment and cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
SECTION 7. HANDLING AND STORAGE

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling: Do not get on skin or clothing. Do not breathe dust. Do not swallow. Avoid contact with eyes. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage: Keep in properly labeled containers. Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types: Strong oxidizing agents Organic peroxides Explosives Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Respirable)</td>
<td>5 mg/m³</td>
<td>NIOSH REL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (total)</td>
<td>10 mg/m³</td>
<td>NIOSH REL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (total dust)</td>
<td>15 mg/m³</td>
<td>OSHA Z-1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (respirable fraction)</td>
<td>5 mg/m³</td>
<td>OSHA Z-1</td>
</tr>
<tr>
<td>Ezetimibe</td>
<td>163222-33-1</td>
<td>TWA</td>
<td>25 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>250 µg/100 cm²</td>
<td>Internal</td>
</tr>
<tr>
<td>Simvastatin</td>
<td>79902-63-9</td>
<td>TWA</td>
<td>25 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Further information: DSEN</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>250 µg/100 cm²</td>
<td>Internal</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>TWA (Inhalable fraction)</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Respirable fraction)</td>
<td>3 mg/m³</td>
<td>ACGIH</td>
</tr>
</tbody>
</table>
Engineering measures: All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection: General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection

Material: Chemical-resistant gloves

Remarks: Consider double gloving.

Eye protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance</td>
<td>powder</td>
</tr>
<tr>
<td>Color</td>
<td>No data available</td>
</tr>
<tr>
<td>Odor</td>
<td>No data available</td>
</tr>
<tr>
<td>Odor Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>No data available</td>
</tr>
<tr>
<td>Evaporation rate</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>May form explosive dust-air mixture during processing, handling or other means.</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapor pressure</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative vapor density</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative density</td>
<td>No data available</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td>Water solubility</td>
</tr>
<tr>
<td>Relative vapor density</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative density</td>
<td>No data available</td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water</td>
<td>No data available</td>
</tr>
<tr>
<td>Autoignition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity</td>
<td>Viscosity, kinematic</td>
</tr>
<tr>
<td>Explosive properties</td>
<td>Not explosive</td>
</tr>
<tr>
<td>Oxidizing properties</td>
<td>The substance or mixture is not classified as oxidizing.</td>
</tr>
<tr>
<td>Molecular weight</td>
<td>No data available</td>
</tr>
<tr>
<td>Particle size</td>
<td>No data available</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET
Ezetimibe / Simvastatin Formulation

Version: 6.2
Revision Date: 09/13/2019
SDS Number: 28137-00014
Date of last issue: 04/24/2019
Date of first issue: 11/04/2014

SECTION 10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions:
May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

Conditions to avoid:
Heat, flames and sparks.
Avoid dust formation.

Incompatible materials:
Oxidizing agents

Hazardous decomposition products:
No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure
Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Components:

Cellulose:
Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity:
LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity:
LD50 (Rabbit): > 2,000 mg/kg

Ezetimibe:
Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
LD50 (Mouse): > 5,000 mg/kg
LD50 (Dog): > 3,000 mg/kg

Acute inhalation toxicity: Remarks: No data available

Acute dermal toxicity: Remarks: No data available

Acute toxicity (other routes of administration)
LD50 (Rat): > 2,000 mg/kg
Application Route: Intraperitoneal
LD50 (Mouse): > 1,000 - < 2,000 mg/kg
Application Route: Intraperitoneal
Simvastatin:
Acute oral toxicity: LD50 (Rat): 5,000 mg/kg
LD50 (Mouse): 3,800 mg/kg

Magnesium stearate:
Acute oral toxicity: LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity: LD50 (Rabbit): > 2,000 mg/kg
Remarks: Based on data from similar materials

Skin corrosion/irritation
Causes skin irritation.

Components:

Ezetimibe:
Species: Rabbit
Result: No skin irritation

Simvastatin:
Species: Rabbit
Remarks: Moderate skin irritation

Magnesium stearate:
Species: Rabbit
Result: No skin irritation
Remarks: Based on data from similar materials

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Ezetimibe:
Species: Rabbit
Result: No eye irritation

Simvastatin:
Species: Rabbit
Remarks: Slight irritation

Magnesium stearate:
Species: Rabbit
Result: No eye irritation
Remarks: Based on data from similar materials
Respiratory or skin sensitization

Skin sensitization
May cause an allergic skin reaction.

Respiratory sensitization
Not classified based on available information.

Components:

Ezetimibe:
Test Type: Maximization Test
Species: Guinea pig
Result: negative

Simvastatin:
Assessment: Probability or evidence of skin sensitization in humans
Result: positive

Magnesium stearate:
Test Type: Maximization Test
Routes of exposure: Skin contact
Species: Guinea pig
Method: OECD Test Guideline 406
Result: negative
Remarks: Based on data from similar materials

Germ cell mutagenicity
Not classified based on available information.

Components:

Cellulose:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Ezetimibe:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Metabolic activation: with and without metabolic activation
Result: negative
Test Type: Chromosomal aberration
Test system: Human lymphocytes
Result: negative

Genotoxicity in vivo:
- Test Type: Micronucleus test
  - Species: Mouse
  - Cell type: Bone marrow
  - Application Route: Oral
  - Result: negative

Simvastatin:
- Genotoxicity in vitro:
  - Test Type: Bacterial reverse mutation assay (AMES)
    - Result: negative
  - Test Type: Alkaline elution assay
    - Result: negative
  - Test Type: Chromosomal aberration
    - Result: negative
  - Test Type: In vitro mammalian cell gene mutation test
    - Result: negative

- Genotoxicity in vivo:
  - Test Type: Micronucleus test
    - Species: Mouse
    - Application Route: Oral
    - Result: negative

Germ cell mutagenicity - Assessment:
- Weight of evidence does not support classification as a germ cell mutagen.

Magnesium stearate:
- Genotoxicity in vitro:
  - Test Type: In vitro mammalian cell gene mutation test
    - Result: negative
  - Remarks: Based on data from similar materials
  - Test Type: Chromosome aberration test in vitro
    - Method: OECD Test Guideline 473
    - Result: negative
    - Remarks: Based on data from similar materials
  - Test Type: Bacterial reverse mutation assay (AMES)
    - Result: negative
    - Remarks: Based on data from similar materials

Carcinogenicity:
Not classified based on available information.

Components:

Cellulose:
- Species: Rat
- Application Route: Ingestion
- Exposure time: 72 weeks
- Result: negative
SAFETY DATA SHEET

Ezetimibe / Simvastatin Formulation

Version: 6.2  Revision Date: 09/13/2019  SDS Number: 28137-00014  Date of last issue: 04/24/2019  Date of first issue: 11/04/2014

Ezetimibe:
Species: Rat, female
Application Route: oral (feed)
Exposure time: 104 weeks
Result: negative

Species: Rat, male
Application Route: oral (feed)
Exposure time: 104 weeks
Result: negative

Species: Mouse
Application Route: oral (feed)
Exposure time: 104 weeks
Result: negative

Simvastatin:
Species: Mouse
Application Route: Oral
Exposure time: < 92 weeks
Target Organs: Harderian gland
Tumor Type: Liver, Lungs
Remarks: The significance of these findings for humans is not certain.

Species: Rat
Application Route: Oral
Exposure time: 2 Years
Tumor Type: Liver, Thyroid
Remarks: The significance of these findings for humans is not certain.

IARC
No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA
No component of this product present at levels greater than or equal to 0.1% is on OSHA’s list of regulated carcinogens.

NTP
No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity
Not classified based on available information.

Components:

Cellulose:
Effects on fertility: Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on fetal development: Test Type: Fertility/early embryonic development
Species: Rat
**Ezetimibe**

<table>
<thead>
<tr>
<th>Effects on fertility</th>
<th>Test Type: Fertility/early embryonic development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat, male and female</td>
<td></td>
</tr>
<tr>
<td>Fertility: NOAEL: &gt; 1,000 mg/kg body weight</td>
<td></td>
</tr>
<tr>
<td>Result: No effects on fertility., No fetotoxicity.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Effects on fetal development</th>
<th>Test Type: Development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
<td></td>
</tr>
<tr>
<td>Application Route: Oral</td>
<td></td>
</tr>
<tr>
<td>Developmental Toxicity: NOAEL: &gt; 1,000 mg/kg body weight</td>
<td></td>
</tr>
<tr>
<td>Result: No adverse effects.</td>
<td></td>
</tr>
</tbody>
</table>

**Simvastatin**

<table>
<thead>
<tr>
<th>Effects on fertility</th>
<th>Test Type: Fertility</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat, male</td>
<td></td>
</tr>
<tr>
<td>Application Route: Oral</td>
<td></td>
</tr>
<tr>
<td>Fertility: LOAEL: 25 mg/kg body weight</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Effects on fetal development</th>
<th>Test Type: Embryo-fetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
<td></td>
</tr>
<tr>
<td>Application Route: Oral</td>
<td></td>
</tr>
<tr>
<td>Embryo-fetal toxicity.: NOAEL: 25 mg/kg body weight</td>
<td></td>
</tr>
<tr>
<td>Result: No teratogenic effects., No adverse effects.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Effects on fetal development</th>
<th>Test Type: Embryo-fetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rabbit</td>
<td></td>
</tr>
<tr>
<td>Application Route: Oral</td>
<td></td>
</tr>
<tr>
<td>Embryo-fetal toxicity.: NOAEL: 10 mg/kg body weight</td>
<td></td>
</tr>
<tr>
<td>Result: No teratogenic effects., No adverse effects.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Effects on fetal development</th>
<th>Test Type: Embryo-fetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
<td></td>
</tr>
<tr>
<td>Application Route: Oral</td>
<td></td>
</tr>
<tr>
<td>Embryo-fetal toxicity.: LOAEL: 60 mg/kg body weight</td>
<td></td>
</tr>
<tr>
<td>Result: Teratogenic potential.</td>
<td></td>
</tr>
<tr>
<td>Remarks: Based on data from similar materials</td>
<td></td>
</tr>
</tbody>
</table>

**Magnesium stearate**

<table>
<thead>
<tr>
<th>Effects on fertility</th>
<th>Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
<td></td>
</tr>
<tr>
<td>Application Route: Ingestion</td>
<td></td>
</tr>
<tr>
<td>Method: OECD Test Guideline 422</td>
<td></td>
</tr>
<tr>
<td>Result: negative</td>
<td></td>
</tr>
</tbody>
</table>
Ezetimibe / Simvastatin Formulation

Remarks: Based on data from similar materials

Effects on fetal development
Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT-single exposure
Not classified based on available information.

STOT-repeated exposure
Causes damage to organs (Liver, muscle, optic nerve, Eye) through prolonged or repeated exposure.

Components:

Simvastatin:
Target Organs: Liver, muscle, optic nerve, Eye
Assessment: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Cellulose:
Species: Rat
NOAEL: >= 9,000 mg/kg
Application Route: Ingestion
Exposure time: 90 Days

Ezetimibe:
Species: Dog
NOAEL: 1,000 mg/kg
Application Route: Oral
Exposure time: 90 d
Remarks: No significant adverse effects were reported

Species: Rat
NOAEL: 1,500 mg/kg
Application Route: Oral
Exposure time: 90 d
Remarks: No significant adverse effects were reported

Species: Mouse
NOAEL: 500 mg/kg
Application Route: Oral
Exposure time: 90 d
Remarks: No significant adverse effects were reported

Species: Dog
NOAEL: 300 mg/kg
Application Route: Oral
Exposure time : 1 y
Remarks : No significant adverse effects were reported

**Simvastatin:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>5 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>30 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>14 - 104 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Liver, Testis, Musculo-skeletal system, Eye</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>50 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>14 - 104 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Liver, Testis, Eye</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Rabbit</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>30 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>50 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>90 Days</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Liver, Kidney</td>
</tr>
</tbody>
</table>

**Magnesium stearate:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>&gt; 100 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Ingestion</td>
</tr>
<tr>
<td>Exposure time</td>
<td>90 Days</td>
</tr>
<tr>
<td>Remarks</td>
<td>Based on data from similar materials</td>
</tr>
</tbody>
</table>

Aspiration toxicity
Not classified based on available information.

**Components:**

**Ezetimibe:**
Not applicable

Experience with human exposure

**Components:**

**Ezetimibe:**

Ingestion : Symptoms: Headache, Nausea, Vomiting, Diarrhea, flatulence, muscle pain, upper respiratory tract infection, Back pain, joint pain

**Simvastatin:**

Skin contact : Remarks: May produce an allergic reaction.
Ingestion : Target Organs: Liver
Symptoms: upper respiratory tract infection, Headache, Abdominal pain, constipation, Nausea
Target Organs: Musculo-skeletal system
## SECTION 12. ECOLOGICAL INFORMATION

**Ecotoxicity**

### Components:

**Cellulose:**
- **Toxicity to fish:** LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
  - Exposure time: 48 h
  - Remarks: Based on data from similar materials

**Ezetimibe:**
- **Toxicity to fish:** LC50 (Pimephales promelas (fathead minnow)): > 0.125 mg/l
  - Exposure time: 96 h
  - Method: OECD Test Guideline 203
  - Remarks: No toxicity at the limit of solubility.

**Toxicity to daphnia and other aquatic invertebrates:** EC50 (Daphnia magna (Water flea)): > 4 mg/l
  - Exposure time: 48 h
  - Method: OECD Test Guideline 202
  - Remarks: No toxicity at the limit of solubility.

**Toxicity to algae/aquatic plants:** EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.317 mg/l
  - Exposure time: 96 h
  - Method: OECD Test Guideline 201
  - Remarks: No toxicity at the limit of solubility.
  - NOEC (Pseudokirchneriella subcapitata (green algae)): 0.317 mg/l
  - Exposure time: 96 h
  - Method: OECD Test Guideline 201
  - Remarks: No toxicity at the limit of solubility.

**Toxicity to fish (Chronic toxicity):** NOEC (Pimephales promelas (fathead minnow)): 0.051 mg/l
  - Exposure time: 33 d
  - Method: OECD Test Guideline 210

  NOEC (Cyprinodon variegatus (sheepshead minnow)): 4 mg/l
  - Exposure time: 7 d
  - Remarks: No toxicity at the limit of solubility.

**Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):** NOEC (Daphnia magna (Water flea)): 0.282 mg/l
  - Exposure time: 21 d
  - Remarks: No toxicity at the limit of solubility.

**Toxicity to microorganisms:** EC50: > 4.4 mg/l
  - Exposure time: 3 h
  - Test Type: Respiration inhibition
  - Method: OECD Test Guideline 209
  - Remarks: No toxicity at the limit of solubility.

  NOEC: 4.4 mg/l
  - Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility.

**Simvastatin:**

**Toxicity to fish**

<table>
<thead>
<tr>
<th>Test substance</th>
<th>EC50 (Pimephales promelas (fathead minnow))</th>
<th>Exposure time: 96 h</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2.91 mg/l</td>
<td></td>
</tr>
</tbody>
</table>

Method: OECD Test Guideline 203

**Toxicity to daphnia and other aquatic invertebrates**

<table>
<thead>
<tr>
<th>Test substance</th>
<th>EC50 (Daphnia magna (Water flea))</th>
<th>Exposure time: 48 h</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3.5 mg/l</td>
<td></td>
</tr>
</tbody>
</table>

Method: OECD Test Guideline 202

**Toxicity to algae/aquatic plants**

<table>
<thead>
<tr>
<th>Test substance</th>
<th>EC50 (Pseudokirchneriella subcapitata (green algae))</th>
<th>Exposure time: 96 h</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&gt; 25 mg/l</td>
<td></td>
</tr>
</tbody>
</table>

NOEC (Pseudokirchneriella subcapitata (green algae)): 25 mg/l
Exposure time: 96 h

**Toxicity to microorganisms**

<table>
<thead>
<tr>
<th>Test substance</th>
<th>EC50: &gt; 30 mg/l</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Exposure time: 3 h</td>
</tr>
</tbody>
</table>

Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 21 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

**Magnesium stearate:**

**Toxicity to fish**

<table>
<thead>
<tr>
<th>Test substance</th>
<th>LC50 (Leuciscus idus (Golden orfe))</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&gt; 100 mg/l</td>
</tr>
</tbody>
</table>

Exposure time: 48 h
Method: DIN 38412
Remarks: Based on data from similar materials

**Toxicity to daphnia and other aquatic invertebrates**

<table>
<thead>
<tr>
<th>Test substance</th>
<th>EL50 (Daphnia magna (Water flea))</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&gt; 1 mg/l</td>
</tr>
</tbody>
</table>

Exposure time: 47 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials
No toxicity at the limit of solubility.

**Toxicity to algae/aquatic plants**

<table>
<thead>
<tr>
<th>Test substance</th>
<th>EL50 (Pseudokirchneriella subcapitata (green algae))</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&gt; 1 mg/l</td>
</tr>
</tbody>
</table>

Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials
No toxicity at the limit of solubility.

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to microorganisms: EC10 (Pseudomonas putida): > 100 mg/l
Exposure time: 16 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Persistence and degradability

**Components:**

**Cellulose:**
Biodegradability: Result: Readily biodegradable.

**Ezetimibe:**
Biodegradability: Result: Not readily biodegradable.
Biodegradation: 6.8%
Exposure time: 28 d

Stability in water: Hydrolysis: 50 % (4.5 d)
Method: OECD Test Guideline 111

**Simvastatin:**
Biodegradability: Result: rapidly degradable

Stability in water: Hydrolysis: 50 % (3.2 d)

**Magnesium stearate:**
Biodegradability: Result: Not biodegradable.
Remarks: Based on data from similar materials

Bioaccumulative potential

**Components:**

**Ezetimibe:**
Bioaccumulation: Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 173
Exposure time: 97 d
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water: log Pow: 4.36

**Simvastatin:**
Partition coefficient: n-octanol/water: log Pow: > 4.07

**Magnesium stearate:**
Partition coefficient: n-octanol/water: log Pow: > 4
octanol/water

Mobility in soil

Components:

Ezetimibe:
Distribution among environmental compartments: log Koc: 4.35
Method: OECD Test Guideline 106

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
UN number: UN 3077
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Simvastatin)
Class: 9
Packing group: III
Labels: 9

IATA-DGR
UN/ID No.: UN 3077
Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (Ezetimibe, Simvastatin)
Class: 9
Packing group: III
Labels: Miscellaneous
Packing instruction (cargo aircraft): 956
Packing instruction (passenger aircraft): 956
Environmentally hazardous: yes

IMDG-Code
UN number: UN 3077
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Simvastatin)
Class: 9
Packing group: III
Labels: 9
SAFETY DATA SHEET

Ezetimibe / Simvastatin Formulation

Version 6.2  Revision Date: 09/13/2019  SDS Number: 28137-00014  Date of last issue: 04/24/2019

Date of first issue: 11/04/2014

EmS Code: F-A, S-F
Marine pollutant: yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation

49 CFR
UN/ID/NA number: UN 3077
Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (Ezetimibe, Simvastatin)
Class: 9
Packing group: III
Labels: CLASS 9
ERG Code: 171
Marine pollutant: yes (Ezetimibe, Simvastatin)
Remarks: Above applies only to containers over 119 gallons or 450 liters., Shipment by ground under DOT is non-regulated; however it may be shipped per the applicable hazard classification to facilitate multi-modal transport involving ICAO (IATA) or IMO.

Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

EPCRA - Emergency Planning and Community Right-to-Know
CERCLA Reportable Quantity
This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity
This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity
This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards: Combustible dust
Skin corrosion or irritation
Respiratory or skin sensitization
Specific target organ toxicity (single or repeated exposure)

SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations
Pennsylvania Right To Know
D-Glucose, 4-O-.beta.-D-galactopyranosyl-, monohydrate 64044-51-5
Cellulose 9004-34-6
California Prop. 65
WARNING: This product can expose you to chemicals including tert-Butyl-4-methoxyphenol, which is/are known to the State of California to cause cancer. For more information go to www.P65Warnings.ca.gov.

California Permissible Exposure Limits for Chemical Contaminants

<table>
<thead>
<tr>
<th>Chemical</th>
<th>Limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
</tr>
</tbody>
</table>

The ingredients of this product are reported in the following inventories:

- AICS: not determined
- DSL: not determined
- IECSC: not determined

SECTION 16. OTHER INFORMATION

Further information

**NFPA 704:**

- Flammability: 1
- Physical Hazard: 0
- Health: 2
- Special Hazard: *

**HMIS® IV:**

- Health: *
- Flammability: 3
- Physical Hazard: 0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

**Full text of other abbreviations**

- ACGIH: USA. ACGIH Threshold Limit Values (TLV)
- NIOSH REL: USA. NIOSH Recommended Exposure Limits
- OSHA Z-1: USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
- ACGIH / TWA: 8-hour, time-weighted average
- NIOSH REL / TWA: Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
- OSHA Z-1 / TWA: 8-hour time weighted average

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation,
and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet:

Revision Date: 09/13/2019

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

US / Z8